Antituberculous composition comprising oxazole compounds

An antituberculous therapeutic drug comprising:

• (I) at least one selected from the group consisting of 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compounds represented by general formula (I):
• [wherein R1 represents a hydrogen atom or C1-6 alkyl group, n represents an integer of 0-6, and R2 represents any group of the following general formulas (A)-(G), wherein
• the group represented by the general formula (A) is:
• wherein R3 represents any group of the following (1)-(6):
• (1) a phenoxy group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring);
• (2) a phenyl C1-6 alkoxy group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring);
• (3) —NR4R5 group, wherein R4 represents a hydrogen atom or C1-6 alkyl group and R5 represents a phenyl group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring);
• (4) a phenyl C1-6 alkyl group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring);
• (5) a phenoxy C1-6 alkyl group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring);
• and
• (6) a benzofuryl C1-6 alkyl group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the benzofuran ring);
• the group represented by the general formula (B) is:
• wherein R6 represents a phenyl group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring);
• the group represented by the general formula (C) is:
• wherein R7 represents a phenyl C2-10 alkenyl group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring) or a biphenyl C1-6 alkyl group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring);
• the group represented by the general formula (D) is:
• wherein R8 represents a phenyl C1-6 alkyl group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring);
• the group represented by the general formula (E) is:
• (wherein R8 is as described above);
• and
• the group represented by the general formula (F) is:
• (wherein R6 is as described above), the group represented by the general formula (G) is:
• (wherein R8 is as described above)],
• optically active forms thereof and pharmacologically acceptable salts thereof, and
• (II) at least one drug selected from the group consisting of primary antituberculous drugs, secondary antituberculous drugs, quinolone antibacterial drugs, macrolide antibacterial drugs, sulfa drugs, and anti-HIV drugs.